Search

everythinglearnresearchcommunity

for

Search:↓

The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.

The user is considering adding Alfatradiol or Pyralutamide to their current hair loss treatment of oral Dutasteride and Minoxidil. They are seeking advice on experiences and purchasing options for these products in the US.

The user treated seborrheic dermatitis by cutting sugar, improving sleep, using four different shampoos, and occasionally using steroids. Their hair is growing back thicker and new hair is appearing.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.

The user has been on finasteride for 18 months and added dutasteride after the first 6 months, with no hair regrowth observed. Bloodwork shows normal levels of DHT despite the use of both medications.

The conversation humorously discusses an extensive and exaggerated hair loss treatment regimen, including finasteride, dutasteride, minoxidil, pyrilutamide, RU58841, and various other therapies. Despite the numerous treatments, the effectiveness is questioned, and the user humorously considers adding more minoxidil.

The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.

The conversation discusses hair loss treatments, focusing on vitamin D and B12 deficiencies, and mentions using finasteride. It also suggests getting a biopsy to differentiate between MPB and other conditions.

Hair loss can be influenced by chronic low-level allergies, and treatments like fexofenadine or topical cetirizine may help with regrowth. The user avoids finasteride, dutasteride, and minoxidil, and has tried Regenera Activa and PRF sessions.

User discusses Latanoprost as potential hair loss treatment and considers combining it with oral minoxidil for better results. Seeking opinions on effectiveness and expense.

The user is currently using Minoxidil with melatonin, rosemary, peppermint, azelaic acid, and RU58841 for hair loss and plans to add fluridil and Pyrilutamide. They seek advice on the best Pyrilutamide source, noting Actifolic worked briefly.

A 24-year-old has been using oral finasteride and topical minoxidil for six months with minimal progress in hair regrowth, despite starting derma rolling and considering telogen effluvium as a possible cause. Suggestions include switching to oral minoxidil, adding dutasteride, and continuing microneedling for better results.

The conversation discusses hair loss caused by Trenbolone use, with suggestions to stop using it and consider treatments like Minoxidil, Dutasteride, and RU58841. It highlights that Minoxidil may temporarily regrow hair, but stopping Trenbolone is crucial to prevent further hair loss.

The user has been taking 1mg of finasteride daily for a year, maintaining hair density without regrowth. They are considering oral minoxidil for regrowth, avoiding topical minoxidil due to its toxicity to cats, despite concerns about heart side effects.

The user experienced significant hair improvement with minoxidil and finasteride but later faced shedding and diffused thinning after developing seborrheic dermatitis. They are seeking advice after trying treatments like ketoconazole, coal tar shampoos, fluconazole, and hydrocortisone cream.

The user has been using Minoxidil, Ketoconazole shampoo, and a dermastamp for 7 months and experienced a period with no shedding, but is now shedding about 100 hairs a day and is questioning if this is a result of the treatment or their normal hair loss. They are unable to start finasteride and are considering stopping the treatment due to the shedding.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

User experiences slow hair regrowth despite using finasteride, topical minoxidil, and supplements like biotin, zinc, and collagen. They seek advice on addressing overall slow hair regrowth.

Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.

The conversation is about the effectiveness of a hair loss treatment product containing 0.01% Latanoprost, with the user considering trying it as a vehicle for RU58841. The user questions whether the dosage is too low to be effective.

The user plans to pause finasteride for two months to test its effects on mood and productivity, then switch to Pyrilutamide while monitoring hormone levels. Concerns are raised about potential hair loss and the effectiveness of Pyrilutamide compared to finasteride.

User discusses scalp micropigmentation for denser hair appearance and its benefits compared to lifelong treatments. Special ink is used, which can fade and blur over time but can be topped up.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

This post and conversation are about the molecular mechanisms triggered by microneedling, specifically its effects on inflammation, tissue remodeling, epithelial proliferation, differentiation, and collagen synthesis. The discussion highlights the potential benefits of microneedling for hair loss treatment.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

The user is experiencing hair regrowth with oral minoxidil and dutasteride but still has fragile hairs that easily pluck out from the front center. Despite improvements, the user is concerned about the persistent fragility and shedding of these hairs.

Using a low dose of topical Tamoxifen effectively reduces gynecomastia caused by finasteride, with minimal side effects. The solution involves mixing Tamoxifen with ethanol and propylene glycol, applied daily to the chest.

The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.